Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07330778
PHASE1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Sponsor: Celldex Therapeutics
View on ClinicalTrials.gov
Summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Official title: An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-02
Completion Date
2027-03
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Interventions
DRUG
CDX-622
Administered Intravenously
Locations (2)
The University of Kansas Medical Center
Kansas City, Kansas, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States